Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 4/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22899036 | 0.89 | GSK3A (0.34) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL22899014 | 0.86 | — | — | |
| SCHEMBL22898925 | 0.78 | RGS4 (0.44) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL22899087 | 0.78 | RGS4 (0.44) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL22899002 | 0.76 | — | — | |
| SCHEMBL23004665 | 0.73 | GSK3A (0.35) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL22899038 | 0.73 | GSK3A (0.35) | — | |
| SCHEMBL331903 | 0.72 | PDE4A (0.47) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL17537380 | 0.70 | ADORA2B (0.40) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL17537363 | 0.70 | ADORA2B (0.40) | PDE4AADORA2APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210020991-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210020991-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | SLC9B2, SLC9A1, SLC9A2 | PDE4A 3232/4885ADORA2A 4139/4885PDE4B 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.